Policy Watch: 20 Regulatory Updates — March 14, 2026

Schedules of Controlled Substances: Temporary Placement of Bromazolam in Schedule I

Regulatory Action Summary This temporary scheduling of bromazolam (a benzodiazepine analog) in Schedule I has minimal direct relevance to cannabis medicine, though it reflects DEA oversight of controlled substance analogs that patients might use concurrently with cannabis.

Schedules of Controlled Substances: Placement of Butonitazene, Flunitazene, and Metodesnitazene in Schedule I

This DEA action schedules three synthetic opioids as Schedule I controlled substances, with no direct relevance to cannabis medicine practice or patient care.

Schedules of Controlled Substances: Placement of Ethylphenidate in Schedule I

Regulatory Summary This DEA action schedules ethylphenidate (a stimulant) as a controlled substance, relevant to cannabis clinicians managing patients concurrently using stimulants or treating ADHD as an alternative consideration.

Schedules of Controlled Substances: Temporary Placement of N-pyrrolidino metonitazene and N-pyrrolidino protonitazene in Schedule I

This regulatory action schedules synthetic opioids, not cannabis compounds, and has minimal direct relevance to cannabis medicine clinicians or patients unless treating co-occurring opioid use disorders.

Importer of Controlled-Biopharmaceutical(2024-20085)DEA1425

Regulatory Summary DEA permit 2024-20085 authorizes controlled-biopharmaceutical importation, potentially enabling clinical access to cannabis-derived or cannabis-related pharmaceutical products for licensed practitioners and patients.

Schedules of Controlled Substances: Temporary Placement of N-Desethyl Isotonitazene and N-Piperidinyl Etonitazene in Schedule I

This regulation schedules synthetic opioid analogs but does not directly affect cannabis medicine; however, it reflects DEA enforcement priorities that may influence controlled substance scheduling policies affecting cannabinoid compounds.

Schedules of Controlled Substances: Rescheduling of Marijuana

Regulatory Summary The DEA rescheduled marijuana from Schedule I to Schedule III, enabling increased research opportunities and potentially facilitating clinical prescribing while maintaining federal restrictions on cannabis use.

Definition of Engaged in the Business as a Dealer in Firearms

This firearms regulation does not directly apply to cannabis clinicians or patients, as it addresses dealer licensing requirements under federal firearms law rather than cannabis medicine practice or patient access.

Schedules of Controlled Substances: Placement of Etodesnitazene, N-Pyrrolidino etonitazene, and Protonitazene in Schedule I

Regulatory Summary The DEA placed three synthetic opioid analogs (etodesnitazene, N-pyrrolidino etonitazene, protonitazene) into Schedule I, establishing legal controls on substances unrelated to cannabis medicine or patient care.

Schedules of Controlled Substances: Placement of Butonitazene, Flunitazene, and Metodesnitazene Substances in Schedule I

This regulation schedules three synthetic opioids under Schedule I; it does not directly impact cannabis medicine but reflects broader controlled substance policy that may influence prescribing considerations for cannabis-using patients.

Schedules of Controlled Substances: Placement of 2-Methyl AP-237 in Schedule I

The DEA classified 2-Methyl AP-237, a synthetic opioid, as Schedule I, which does not directly affect cannabis regulation but reflects broader controlled substance policy relevant to pain management alternatives clinicians may discuss.

Schedules of Controlled Substances: Placement of 2,5-dimethoxy-4-iodoamphetamine and 2,5-dimethoxy-4-chloroamphetamine in Schedule I

Regulatory Summary This DEA action schedules two synthetic amphetamines as controlled substances; it has no direct relevance to cannabis clinicians or patients, as it concerns separate hallucinogenic compounds outside the cannabis therapeutic domain.

Schedules of Controlled Substances: Temporary Placement of MDMB–4en–PINACA, 4F–MDMB–BUTICA, ADB–4en–PINACA, CUMYL–PEGACLONE, 5F–EDMB–PICA, and MMB–FUBICA into Schedule I

Regulatory Summary The DEA temporarily scheduled six synthetic cannabinoids as Schedule I controlled substances, restricting their availability and establishing legal consequences for possession, relevant to clinicians and patients using or considering cannabis alternatives.

Schedules of Controlled Substances: Placement of Ethylphenidate in Schedule I

This regulatory action schedules ethylphenidate as a controlled substance, which does not directly affect cannabis medicine but establishes precedent for substance scheduling that informs how cannabis derivatives are regulated federally.

Schedules of Controlled Substances: Placement of Metonitazene in Schedule I

Regulatory Summary The DEA placed metonitazene, a synthetic opioid, in Schedule I; this action does not directly affect cannabis regulation but may influence pain management discussions with cannabis-using patients.

Schedules of Controlled Substances: Temporary Placement ofEtizolam, Flualprazolam, Clonazolam, Flubromazolam, and Diclazepam in Schedule I

This regulatory action schedules certain benzodiazzoepines as controlled substances, relevant to cannabis clinicians treating anxiety or seizures who may need to coordinate care with patients using these now-restricted medications.

Importer of Controlled Substances Application Biopharmaceutical Research Company – DEA1224

Regulatory Summary A biopharmaceutical company applied for DEA licensing to import controlled substances, enabling potential development and clinical testing of cannabis-derived medicines under federal regulatory oversight.

Importer of Controlled-Bright Green(2024-20083)DEA1426

Regulatory Summary DEA Import Permit 2024-20083 authorizes controlled substance importation, potentially affecting cannabis clinicians’ and patients’ access to research materials or pharmaceutical cannabinoid products through regulated supply channels.

Importer of Controlled-Cambridge Isotope(2024-20082)DEA1429

Regulatory Summary DEA import authorization for Cambridge Isotope allows controlled substance research materials, potentially supporting cannabis pharmacology and cannabinoid analysis studies relevant to clinical development.

Medicare and Medicaid Programs: Calendar Year 2025 Payment Policies Under the Physician Fee Schedule and Other Changes to Part B Payment and Coverage Policies; etc.

CMS updates 2025 Medicare/Medicaid physician payment policies and Part B coverage, potentially affecting reimbursement rates and covered services for healthcare providers, including those treating cannabis-related conditions.

The majority of these regulatory actions reflect the ongoing challenge of synthetic opioid analogs and designer drugs entering illicit markets faster than scheduling mechanisms can address them, with multiple items targeting nitazene compounds and their chemical variants that have emerged as significant contributors to overdose deaths. Only one item addresses cannabis through rescheduling, while the remainder focus on synthetic cathinones, hallucinogens, benzodiazepines, and other novel psychoactive substances, indicating that the public health burden from these synthetic drugs continues to warrant substantial regulatory attention. From a clinical standpoint, these scheduling actions represent reactive rather than preventive policy tools, as the chemical modifications highlighted here suggest that substance use disorder treatment and overdose prevention programs must remain flexible enough to address drugs that may not yet be formally scheduled.